Sign in
WithdrawnPhase 2/3

Tailoring Obesity Treatment Trial

Key facts

Who runs it
Esbjerg Hospital - University Hospital of Southern Denmark
Where
Denmark1 site in 1 countryChoose a country to see its sites
Status
Withdrawn
Phase
Phase 2/3
Started
1 Apr 2025
Ended
1 Apr 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Pramlintide Acetate 1 MG/ML
  • Semaglutide Pen Injector
  • Sodium Chloride 0.9% Inj
Record updated
17 April 2026
Why it stopped
suspended by the danish medical agency

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • BMI ≧ 30kg/m2
  • HbA1c 39-47 mmol/mol (pre-diabetes)
  • Male or female
  • Aged >18 years of age and <70 years
  • Negative pregnancy test, and willing to use contraceptives during the study period

Who cannot take part

  • Current or recent (<6 months) treatment with GLP1 RA's
  • Previous gastrointestinal surgery that might affect gastric emptying, nutritional absorption and postprandial GI peptide production
  • Use of any antipsychotic drugs
  • Use of any antiresorptive or bone-anabolic drugs or fractures within < 6 months
  • Newly (< 3 months) initiated hormonal contraceptive or other hormone therapy
  • Presence of diabetes with or without treatment
  • History of acute or chronic pancreatitis
  • Chronic kidney disease
  • Presence of Binge eating disorder
  • Use of systemic oral glucocorticoids within < 6 months
  • Recent (<3 months) weight loss ≧ 1% of body weight

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The two main aims of this clinical study is;

Read full original descriptionShow less

1. To investigate if the results from a series of physiological tests and questionnaires prior to treatment, can be used to predict the treatment response to obesity medication 2. To investigate the effect of combining semaglutide and pramlintide on various aspects of appetite, food preference and eating habits.

The study is planed as a 26 week, double blinded, randomized, placebo controlled trial. The goal is to include N=40. They will all receive weekly semaglutide injections. After 24 weeks they will be randomized to receive either an amylin analog (pramlintide) or placebo as a continuous infusion for two weeks, in addition to weekly semaglutide.

The results from this study will contribute to identifying possible predictors of treatment response, enabling optimal individualized medical weight loss treatment. As well as providing knowledge on the complex interplay between incretin hormones and their effects on appetite and eating habits.

The 2 groups in the trial

  • Semaglutide and placeboExisting treatment, for comparison

    All subjects will receive weekly semaglutide inj. for 26 weeks. After 24 weeks of treatment, this group will be randomized to receive placebo, in addition to semaglutide for the last two weeks of the study.

    Treatment: Semaglutide Pen Injector and Sodium Chloride 0.9% Inj

  • Semaglutide and pramlintideTreatment being tested

    All subjects will receive weekly semaglutide inj. for 26 weeks. After 24 weeks of treatment, this group will be randomized to receive pramlintide, in addition to semaglutide for the last two weeks of the study.

    Treatment: Pramlintide Acetate 1 MG/ML and Semaglutide Pen Injector

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
The Impact of Pramlintide on Top of Semaglutide in Obese People With Prediabetes
Record updated
17 April 2026